Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Mark Roschewski, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Matthias Holdhoff, MD PhD, Lode J. Swinnen, MB ChB, Michael Glantz, MD PhD, Craig A. Portell, MD, Jakub Svoboda, MD, Rafic Farah, MD, Michail S. Lionakis, MD ScD, Louis Staudt, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2875.

https://doi.org/10.1182/blood-2019-123552

Published: 2019

Journal Articles

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, Jagan R. Muppidi, MD PhD, Craig A. Portell, MD, Rafic Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Lydia L. Chou, CRNP, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis Staudt, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2867.

https://doi.org/10.1182/blood-2019-125990

Published: 2019

Journal Articles

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Asha Ricciuti, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, James M. Rossetti, DO, Yongli Shuai, PhD, Daniel Normolle, PhD, Rahim Remtulla, MD, Shawn Tahata, MD, Michael Boyiadzis, MD, Annie Im, MD

Blood (2018) 132 (Supplement 1): 4000.

https://doi.org/10.1182/blood-2018-99-113935

Published: 2018

Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Michael Boyiadzis, MD MHSc, Mounzer Agha, MD, Robert L Redner, MD, Alison Sehgal, MD, Annie Im, MD, Jing-Zhou Hou, Rafic Farah, MD, Kathleen A. Dorritie, MD, Anastasios Raptis, MD PhD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Hans Klingemann, MD PhD, Hong Wang, PhD, Natalia Lapteva, PhD, Mei Zhuyong, MD, Lisa H Butterfield, PhD, Cliona M. Rooney, PhD, Theresa L Whiteside, PhD

Blood (2016) 128 (22): 1649.

https://doi.org/10.1182/blood.V128.22.1649.1649

Published: 2016

Journal Articles

Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Annie Im, MD, Mounzer Agha, MD, Anastasios Raptis, MD PhD, Jing-Zhou Hou, MD PhD, Rafic Farah, MD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Robert Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, Ann Welsh, RN, BSN, OCN, Linda Fukas, RN, Christine Tripoli, RN, BSN, Daniel Normolle, PhD, Daniel E Johnson, PhD, Michael Boyiadzis, MD MHSc

Blood (2015) 126 (23): 3739.

https://doi.org/10.1182/blood.V126.23.3739.3739

Published: 2015

Journal Articles

Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Annie Im, MD, Jing-Zhou Hou, MD PhD, Anastasios Raptis, MD, Mounzer Agha, MD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, Ann Welsh, RN, Daniel E. Johnson, PhD, Daniel Normolle, PhD, Michael Boyiadzis, MD

Blood (2014) 124 (21): 2265.

https://doi.org/10.1182/blood.V124.21.2265.2265

Published: 2014

NARROW

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Phase 2 Study of Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only